Guilin Sanjin Pharmaceutical Co Ltd (002275) — Working Capital to Net Assets Ratio
Guilin Sanjin Pharmaceutical Co Ltd (002275) has a Working Capital to Net Assets ratio of 52.6% as of September 2025. Working capital of CN¥1.71 Billion (current assets of CN¥2.51 Billion minus current liabilities of CN¥801.72 Million) is measured against net assets of CN¥3.24 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See defensive interval ratio of Guilin Sanjin Pharmaceutical Co Ltd to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Guilin Sanjin Pharmaceutical Co Ltd Working Capital to Net Assets (2006–2024)
This chart shows how Guilin Sanjin Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 19 annual periods from 2006 to 2024. As of September 2025, the ratio stands at 52.6%, reflecting working capital of CN¥1.71 Billion against net assets of CN¥3.24 Billion CNY. For the complete balance sheet picture, see Guilin Sanjin Pharmaceutical Co Ltd (002275) total assets.
Annual Working Capital to Net Assets for Guilin Sanjin Pharmaceutical Co Ltd (2006–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Guilin Sanjin Pharmaceutical Co Ltd from 2006 to 2024, covering 19 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check financial resilience of Guilin Sanjin Pharmaceutical Co Ltd to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 52.1% | CN¥1.57 Billion | CN¥3.01 Billion | CN¥2.56 Billion | CN¥995.46 Million | ▲ +5.9 pp |
| 2023 | 46.2% | CN¥1.30 Billion | CN¥2.82 Billion | CN¥2.20 Billion | CN¥893.83 Million | ▼ -5.3 pp |
| 2022 | 51.5% | CN¥1.45 Billion | CN¥2.81 Billion | CN¥2.30 Billion | CN¥846.94 Million | ▼ -5.7 pp |
| 2021 | 57.2% | CN¥1.62 Billion | CN¥2.84 Billion | CN¥2.45 Billion | CN¥829.23 Million | ▼ -3.3 pp |
| 2020 | 60.5% | CN¥1.79 Billion | CN¥2.96 Billion | CN¥2.38 Billion | CN¥589.31 Million | ▲ +4.3 pp |
| 2019 | 56.2% | CN¥1.58 Billion | CN¥2.82 Billion | CN¥1.99 Billion | CN¥405.27 Million | ▼ -2.3 pp |
| 2018 | 58.5% | CN¥1.64 Billion | CN¥2.81 Billion | CN¥2.13 Billion | CN¥484.99 Million | ▲ +2.5 pp |
| 2017 | 56.0% | CN¥1.49 Billion | CN¥2.65 Billion | CN¥1.95 Billion | CN¥463.74 Million | ▲ +5.1 pp |
| 2016 | 50.9% | CN¥1.23 Billion | CN¥2.43 Billion | CN¥1.58 Billion | CN¥342.22 Million | ▼ -1.7 pp |
| 2015 | 52.5% | CN¥1.23 Billion | CN¥2.34 Billion | CN¥1.54 Billion | CN¥310.00 Million | ▼ -3.1 pp |
| 2014 | 55.6% | CN¥1.29 Billion | CN¥2.32 Billion | CN¥1.64 Billion | CN¥350.24 Million | ▼ -5.4 pp |
| 2013 | 61.0% | CN¥1.34 Billion | CN¥2.20 Billion | CN¥1.71 Billion | CN¥365.18 Million | ▼ -6.9 pp |
| 2012 | 67.9% | CN¥1.41 Billion | CN¥2.08 Billion | CN¥1.73 Billion | CN¥315.12 Million | ▼ -4.5 pp |
| 2011 | 72.4% | CN¥1.44 Billion | CN¥1.98 Billion | CN¥1.64 Billion | CN¥204.20 Million | ▼ -2.9 pp |
| 2010 | 75.3% | CN¥1.35 Billion | CN¥1.80 Billion | CN¥1.53 Billion | CN¥175.28 Million | ▼ -7.1 pp |
| 2009 | 82.4% | CN¥1.47 Billion | CN¥1.78 Billion | CN¥1.74 Billion | CN¥272.31 Million | ▲ +26.9 pp |
| 2008 | 55.5% | CN¥437.06 Million | CN¥787.10 Million | CN¥807.04 Million | CN¥369.98 Million | ▲ +1.2 pp |
| 2007 | 54.4% | CN¥396.46 Million | CN¥729.25 Million | CN¥737.23 Million | CN¥340.77 Million | ▲ +10.1 pp |
| 2006 | 44.3% | CN¥277.79 Million | CN¥627.33 Million | CN¥466.73 Million | CN¥188.94 Million | — |